Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 735 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Disease, End-Stage Clear all
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

NCT00646035
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
paricalcitol capsules
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
22
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2008 · Synced Oct 14, 2026, 1:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

RaDIANT Health Systems Intervention

NCT07033117
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Kidney Disease
Interventions
Performance Feedback Reports on Referral and Evaluation Closures, Dialysis Facility Awareness Campaign, Patient Contact via Preferred Method, Phone Call to Dialysis Facility During the Patient's Dialysis Session, Phone Call to Provider, Transplant Referral Communication Platforms or Email to Communicate Patient Status and No-Show, Audit and Tracking of Patient Contact Attempts Prior to Referral Closure
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
14,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 14, 2026, 1:21 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

NCT04523220
View directory record Official record
Conditions
End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
Interventions
BAY1213790 (Osocimab), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Azusa, California • Brawley, California • Encino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 14, 2026, 1:21 PM EDT
Terminated Phase 2 Interventional Results available

Application of Impedance Threshold Device Technologies to Treat and Prevent Hypotension During Dialysis

NCT00576524
View directory record Official record
Conditions
Intradialytic Hypotension, End Stage Renal Disease, Low Blood Pressure
Interventions
ITD, Sham
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Not applicable Interventional

Volume,Sodium and Blood Pressure Management in HD

NCT01766882
View directory record Official record
Conditions
End Stage Renal Failure
Interventions
Lower sodium intervention, Progressive Challenge to Post Dialysis Weight
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Not applicable Interventional

Effects of Intradialytic Exercise as Assessed by Bioimpedance Analysis and Blood Volume Monitoring

NCT01273753
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Intradialytic exercise
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 14, 2026, 1:21 PM EDT
Completed No phase listed Observational

CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients

NCT00227045
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2007 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

NCT01320202
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
Soluble Ferric Pyrophosphate (SFP), Standard dialysate
Drug · Device
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Bakersfield, California • Chula Vista, California • Cudahy, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 2 Interventional

Immune Effects of Vitamin D in Hemodialysis Patients

NCT00686751
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
Interventions
paricalcitol
Drug
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Early Phase 1 Interventional

Carbamylation in Renal Disease-modulation With Amino Acid Therapy

NCT01612429
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Amino acid supplementation
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 14, 2026, 1:21 PM EDT
Completed No phase listed Observational

A Study of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients

NCT01548716
View directory record Official record
Conditions
Vitamin D Deficiency, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 4 Interventional Results available

Improved Induction and Maintenance Immunosuppression in Kidney Transplantation

NCT00556933
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
rabbit anti-thymocyte globulin - single dose, mycophenolate mofetil, rabbit anti-thymocyte globulin - 4 doses, sirolimus, tacrolimus
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 4 Interventional Results available

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

NCT03627299
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
300mg glecaprevir/pibrentasivir 120mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis

NCT03534284
View directory record Official record
Conditions
Insomnia, End Stage Renal Disease
Interventions
Cognitive Behavioral Therapy for Insomnia, Trazodone, Placebo
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 1 Interventional Results available

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

NCT01949532
View directory record Official record
Conditions
Relapsed Multiple Myeloma, End-stage Renal Disease
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Detroit, Michigan • Lake Success, New York • Canton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 14, 2026, 1:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

NCT05287945
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Orellanine
Drug
Lead sponsor
Oncorena AB
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 1:21 PM EDT
Terminated Phase 1 Interventional

Study of GBT021601 in Participants With Renal Impairment

NCT05878704
View directory record Official record
Conditions
Renal Impairment
Interventions
GBT021601
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 14, 2026, 1:21 PM EDT
Completed No phase listed Observational

Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease

NCT03626246
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Secondary Hyperparathyroidism
Interventions
Kidney disease
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions

NCT02059005
View directory record Official record
Conditions
Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia, Acute Myocardial Infarction, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, End-Stage Renal Disease
Interventions
Specialized Community Disease Management, Treatment As Usual
Behavioral
Lead sponsor
Treatment Research Institute
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 14, 2026, 1:21 PM EDT
Recruiting Phase 2Phase 3 Interventional

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
CSL300, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
166
States / cities
Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 1:21 PM EDT
Recruiting Not applicable Interventional

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

NCT06190717
View directory record Official record
Conditions
Diabetes, End Stage Renal Disease
Interventions
EchoMark/EchoSure, Standard of Care
Device · Procedure
Lead sponsor
Sonavex, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional

Prevention of Kidney Transplant Rejection

NCT00005010
View directory record Official record
Conditions
End-Stage Renal Disease, Chronic Allograft Nephropathy
Interventions
Irbesartan, Pravastatin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 14, 2026, 1:21 PM EDT